<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_qA4Yew3">Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome: The TEXTMEDS Randomized Clinical Trial</title>
				<funder>
					<orgName type="full">ANZAC Research Institute (D</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
					<p type="raw">Â© 2022 American Heart Association, Inc.</p>
				</availability>
				<date>May 10, 2022 1453</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>MBBS</roleName><forename type="first">Clara</forename><forename type="middle">K</forename><surname>Chow</surname></persName>
							<email>clara.chow@sydney.edu.au</email>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD;</roleName><forename type="first">Harry</forename><surname>Klimis</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MBBS, BMedSci (Hons I</roleName><surname>Gradcertclinepi</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Aravinda</forename><surname>Thiagalingam</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Julie</forename><surname>Redfern</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>BSc</roleName><forename type="first">Graham</forename><forename type="middle">S</forename><surname>Hillis</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD;</roleName><forename type="first">David</forename><surname>Brieger</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">John</forename><surname>Atherton</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MBBS</roleName><forename type="first">Ravinay</forename><surname>Bhindi</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD, MSc</roleName><forename type="first">Derek</forename><forename type="middle">P</forename><surname>Chew</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Nicholas</forename><surname>Collins</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bmed</forename><forename type="middle">;</forename><surname>Michael</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Andrew</forename><surname>Fitzpatrick</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MBBS, BMedSc</roleName><forename type="first">Craig</forename><surname>Juergens</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MBBS (Hons), DMedSc</roleName><forename type="first">Nadarajah</forename><surname>Kangaharan</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MBBS</roleName><forename type="first">Andrew</forename><surname>Maiorana</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>BSc, MSc, PhD;</roleName><forename type="first">Michele</forename><surname>Mcgrady</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Rohan</forename><surname>Poulter</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MBBS</roleName><forename type="first">Pratap</forename><surname>Shetty</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Jonathon</forename><surname>Waites</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MBBS(Lond</roleName><forename type="first">Hamilton</forename><surname>Christian</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MBBS</roleName><surname>Craig</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD, BMedSci(Hons</roleName><forename type="first">Peter</forename><surname>Thompson</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MD, MBA</roleName><forename type="first">Sandrine</forename><surname>Stepien</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>MSc</roleName><forename type="first">Amy</forename><surname>Huben</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Anthony</forename><surname>Rodgers</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation">The University of Sydney , Faculty of Medicine and Health , Westmead Applied Research Centre , Westmead Hospital , Level 6 , Block K , Entrance 10 , Hawkesbury Road , Westmead , Sydney , NSW , 2145 Australia.</note>
								<orgName type="department" key="dep1">Faculty of Medicine and Health</orgName>
								<orgName type="department" key="dep2">Westmead Applied Research Centre</orgName>
								<orgName type="institution" key="instit1">The University of Sydney</orgName>
								<orgName type="institution" key="instit2">Westmead Hospital</orgName>
								<address>
									<addrLine>Level 6 Block K Entrance 10 Hawkesbury Road Westmead</addrLine>
									<postCode>2145</postCode>
									<settlement>Sydney</settlement>
									<region>NSW</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_7qfuH5n">Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome: The TEXTMEDS Randomized Clinical Trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published">May 10, 2022 1453</date>
						</imprint>
					</monogr>
					<idno type="MD5">267E79545CB4CCD2ADBE07172C05512F</idno>
					<idno type="DOI">10.1161/circulationaha.121.056161</idno>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T10:17+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords xml:id="_eFngZFu">cardiovascular diseases â¼ ehealth â¼ mobile health â¼ myocardial infarction â¼ secondary prevention â¼ telemedicine â¼ text messaging</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_RzjdTMA"><p xml:id="_cGS5CsA"><s xml:id="_KnSsgND">BACKGROUND: TEXTMEDS (Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome) examined the effects of text message-delivered cardiac education and support on medication adherence after an acute coronary syndrome.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_FEcZfht">METHODS:</head><p xml:id="_chMfmJM"><s xml:id="_jUfcvUj">TEXTMEDS was a single-blind, multicenter, randomized controlled trial of patients after acute coronary syndrome.</s><s xml:id="_JUqmxbF">The control group received usual care (secondary prevention as determined by the treating clinician); the intervention group also received multiple motivational and supportive weekly text messages on medications and healthy lifestyle with the opportunity for 2-way communication (text or telephone).</s><s xml:id="_GF2BW5A">The primary end point of self-reported medication adherence was the percentage of patients who were adherent, defined as &gt;80% adherence to each of up to 5 indicated cardioprotective medications, at both 6 and 12 months.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_dxvX8Tx">RESULTS:</head><p xml:id="_ZxA545a"><s xml:id="_tX96hxG">A total of 1424 patients (mean age, 58 years [SD, 11]; 79% male) were randomized from 18 Australian public teaching hospitals.</s><s xml:id="_XFM5GKD">There was no significant difference in the primary end point of self-reported medication adherence between the intervention and control groups (relative risk, 0.93 [95% CI, 0.84-1.03];</s><s xml:id="_Myh7ewa">P=0.15).</s><s xml:id="_xzTJnHC">There was no difference between intervention and control groups at 12 months in adherence to individual medications (aspirin, 96% vs 96%; Î²-blocker, 84% vs 84%; angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, 77% vs 80%; statin, 95% vs 95%; second antiplatelet, 84% vs 84% [all P&gt;0.05]), systolic blood pressure (130 vs 129 mm Hg; P=0.26), low-density lipoprotein cholesterol (2.0 vs 1.9 mmol/L; P=0.34), smoking (P=0.59), or exercising regularly (71% vs 68%; P=0.52).</s><s xml:id="_Ts4ptQu">There were small differences in lifestyle risk factors in favor of intervention on body mass index &lt;25 kg/m 2 (21% vs 18%; P=0.01), eating â¥5 servings per day of vegetables (9% vs 5%; P=0.03), and eating â¥2 servings per day of fruit (44% vs 39%; P=0.01).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_tfuydRd">CONCLUSIONS:</head><p xml:id="_5cZ3SeC"><s xml:id="_gHPVcJv">A text message-based program had no effect on medical adherence but small effects on lifestyle risk factors.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="585.0" lry="783.0"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Kq2gTFG">Chow et al</head><p xml:id="_DABA2RA"><s xml:id="_GHSBWWw">Texts for Cardiovascular Disease Prevention C ardiovascular disease secondary prevention is important and effective in preventing subsequent cardiovascular events, but poorly implemented globally.</s><s xml:id="_NMnhQru">Simple and low-cost methods that are scalable may help address the implementation gap.</s><s xml:id="_rRJdtXf">More than 4.7 billion people own mobile phones and the use of text messages is ubiquitous.</s><s xml:id="_nTbKbG3">Several randomized controlled trials (RCTs) have demonstrated the effectiveness of text message-delivered smoking, physical activity, weight loss, and blood pressure-lowering intervention. <ref type="bibr" target="#b4">[1]</ref><ref type="bibr" target="#b5">[2]</ref></s><s xml:id="_exPZrAp">]<ref type="bibr" target="#b6">[3]</ref><ref type="bibr" target="#b7">[4]</ref><ref type="bibr" target="#b8">[5]</ref><ref type="bibr" target="#b9">[6]</ref><ref type="bibr" target="#b10">[7]</ref><ref type="bibr" target="#b11">[8]</ref><ref type="bibr" target="#b12">[9]</ref><ref type="bibr" target="#b13">[10]</ref><ref type="bibr" target="#b14">[11]</ref> TEXT ME (Tobacco, Exercise and Diet Messages) <ref type="bibr" target="#b6">3</ref> was a single-blind RCT of a 6-month lifestyle-focused text messaging intervention that showed effectiveness, including cost-effectiveness, <ref type="bibr" target="#b14">11</ref> compared with usual care on cardiovascular risk factors (low-density lipoprotein cholesterol [LDL-C], systolic blood pressure [BP], body mass index [BMI], smoking, and physical activity).</s><s xml:id="_5Mphury">TEXT ME and several other texting intervention trials have demonstrated small but positive effects on objective measures of cardiovascular risk factors (eg, LDL-C, BP, smoking cessation, and weight) in patients with coronary heart disease <ref type="bibr" target="#b6">3,</ref><ref type="bibr" target="#b12">9,</ref><ref type="bibr" target="#b13">10</ref> and more recently in overall cardiovascular risk factor control in people without coronary heart disease.</s><s xml:id="_6TU8Qnp"><ref type="bibr">11a</ref> Other text message-based intervention studies have demonstrated improved medical adherence in patients with chronic health conditions. <ref type="bibr" target="#b16">12</ref></s><s xml:id="_m3vYWrw">he TEXTMEDS intervention (Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome), designed to examine whether such a model could be scaled across multiple sites, was implemented after acute coronary syndrome (ACS) admission to improve secondary prevention targets of medical adherence and risk factors.</s><s xml:id="_nDX8gDF">The main aim of the study was to determine in an RCT of patients with ACS the effect of a semipersonalized secondary prevention support program sent by mobile phone text message on the primary outcome of self-reported adherence (the proportion taking appropriate medications at 6 and 12 months) and other risk factor levels at 12 months.</s><s xml:id="_PeueXaB">We also evaluated adherence using linked administrative data, defined as having purchased a medication supply of 5 or more months separately over the 0-to 6-month and 6-to 12-month periods.</s><s xml:id="_Mv2tGyj">We also aimed to determine the acceptability and usefulness of the intervention.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2wG6uxu">METHODS</head><p xml:id="_mZ4p3jW"><s xml:id="_QJFyZYG">The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.</s><s xml:id="_dMQeWNf">On request with a proposal and approval by the TEXTMEDS principal investigators and steering committee, data will be made available for secondary analysis.</s></p><p xml:id="_7hfan4z"><s xml:id="_KMvhKg6">TEXTMEDS is a multicenter RCT that aimed to recruit 1400 patients with previous ACS and follow them up for 12 months.</s><s xml:id="_cuCPtXS">The study was pragmatic in that it aimed to generate knowledge applicable to the potential application of</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_u7PrTMt">Clinical Perspective</head><p xml:id="_9Hfg8rz"><s xml:id="_wgqyGmB">What Is New?</s></p><p xml:id="_UYXGyzX"><s xml:id="_p2Q6jec">â¢ The TEXTMEDS study (Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome) demonstrated implementation of a simple, low-cost, and customized text message-based program requiring minimal local or central staff support across 18 rural and urban centers and 3 time zones in Australia.</s><s xml:id="_3eUNFhv">â¢ The study found no significant effect on the primary outcome of medication adherence or on low-density lipoprotein cholesterol level or blood pressure.</s><s xml:id="_Zqm7n7A">However, intervention participants were more likely to achieve a normal body mass index and to eat guideline-recommended servings of fruit and vegetables.</s><s xml:id="_jPM9Y7S">â¢ Qualitative analysis demonstrated high levels of acceptability, usefulness in being a unified source of information, high program engagement, and emotional support, especially during times of uncertainty.</s></p><p xml:id="_AV96s2E"><s xml:id="_gPEaV3Q">What Are the Clinical Implications?</s></p><p xml:id="_KNxSCvc"><s xml:id="_8m5k9EN">â¢ Customized and personalized text message-based prevention programs are a scalable and low-cost means of delivering consistent education and support to patients after hospitalization for acute cardiac events.</s><s xml:id="_cQhwDwz">â¢ The lack of effect on medical adherence, despite better adherence with healthy lifestyle practices, suggests that external factors, such as cost, may strongly influence medical adherence and may need addressing in addition to education programs to improve medical adherence.</s><s xml:id="_JaQEtmg">â¢ Whereas most new technologies increase overall costs, the linked data analysis found no increased costs and fewer primary care visits and some cardiac tests.</s><s xml:id="_FyGpukV">This could indicate that such programs could be cost-saving but needs formal evaluation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Wywepd4">Nonstandard Abbreviations and Acronyms</head><p xml:id="_uVZmHN7"><s xml:id="_arGFubQ">ACS acute coronary syndrome BMI body mass index BP blood pressure LDL-C low-density lipoprotein cholesterol PBS Pharmaceutical Benefits Scheme RCT randomized controlled trial RR relative risk TEXT ME Tobacco, Exercise and Diet Messages TEXTMEDS Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on July 2, 2025</s></p><p xml:id="_Ax6ADvH"><s xml:id="_DZe6Tw9">the text message-based intervention in everyday clinical practice and compared with usual care.</s><s xml:id="_7bswCdm">As such, the trial was conducted across multiple centers in different urban and rural settings in several Australian states.</s><s xml:id="_euzPFtF">The protocol implemented was version 3.0 and there were no significant amendments made to eligibility criteria (Supplemental Material).</s><s xml:id="_8eeHSp4">The TEXTMEDS study protocol has been published previously. <ref type="bibr" target="#b17">13</ref></s><s xml:id="_aPhmgEX">The statistical analysis plan (version 5.0) is available in the Supplemental Material.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_3Rk3eGr">Trial Oversight</head><p xml:id="_fEYp5GT"><s xml:id="_KWdfbkP">The study was sponsored by a competitive project grant from the National Health and Medical Research Council Australia (grant APP1042290).</s><s xml:id="_A5NXvSj">The study sponsor was The George Institute for Global Health at the University of Sydney and the study was centrally coordinated and managed by staff based mainly at Westmead Hospital and the George Institute.</s><s xml:id="_wvYHhC6">The design and conduct of the study was overseen by a steering committee (the authors and some site principal investigators).</s><s xml:id="_rnpY9yM">The study was approved by an institutional review committee and all participants gave informed consent.</s><s xml:id="_5sKU4HM">Formal ethical approval for this study was obtained from the Western Sydney Local Health District Human Research Ethics Committee (approval HREC2012/12/4.1 [3648] AU RED HREC/13/WMEAD/15).</s><s xml:id="_thJvmBG">Additional approvals were obtained for Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Scheme linked data (March 13, 2013).</s><s xml:id="_WqeDDcM">Participants at baseline to the main study could consent to Medicare Benefits Scheme, PBS, neither, or both.</s><s xml:id="_vgTZdQj">The study was registered with the Australian New Zealand Clinical Trials Registry (URL: <ref type="url" target="https://www.anzctr.org">https://www.anzctr.org</ref>.</s><s xml:id="_4BCgnKM">au/Trial/Registration/TrialReview.aspx?id=364448;</s><s xml:id="_Tk3HK8Q">Unique identifier: ANZCTR ACTRN12613000793718).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_dySePqA">Study Population</head><p xml:id="_g2ducqn"><s xml:id="_G2MgC52">Patients with ACS were recruited from 13 urban and 5 rural centers across 3 time zones and 5 (of 8) states and territories of Australia.</s><s xml:id="_uWqCHua">In brief, the inclusion criteria required confirmed diagnosis of ACS (defined as either an acute myocardial infarction [AMI] or unplanned hospitalization for symptoms consistent with coronary ischemia and documentation of substantial coronary disease or previous revascularized coronary disease); ownership of an operational texting-capable mobile phone; ability to read text messages in English; life expectancy &gt;6 months; and ability to provide informed consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_RbTs6Ed">Trial Procedures</head><p xml:id="_B8Qa8rt"><s xml:id="_K4AuJM9">The intervention program comprised a 1-year program of text messaging, with 4 messages per week for the first 6 months and then decreasing frequency of messaging (3 messages/ week) over the subsequent 6 months.</s><s xml:id="_wTseFkw">The message development, <ref type="bibr" target="#b18">14</ref> the software development, <ref type="bibr" target="#b19">15</ref> and the intervention <ref type="bibr" target="#b17">13</ref> have been described in detail elsewhere.</s><s xml:id="_Mb6YZTN">Both groups received usual care after ACS, defined as secondary prevention as determined by the treating team.</s><s xml:id="_vG8jRCx">Intervention participants also received a customized and personalized text message program.</s><s xml:id="_XAm7rT9">The control group did not receive any regular text messages, but both groups received a welcome message that let them know their group allocation, a message at 6 months indicating they would be called for follow-up soon and to not reveal their allocation, and a similar message at 12 months.</s><s xml:id="_XHFgdqr">The intervention program was customized on health data including aspects of their diet, physical activity capacity, and types of medications they were taking.</s><s xml:id="_YMNHUjx">It was personalized by incorporating the participant's preferred name and the hospital at which the participant was treated.</s><s xml:id="_NYYHmk7">The majority of text messages provided information or support on medications and lifestyle modification.</s><s xml:id="_SkkbEy5">The program was structured such that content was roughly split into 3 modules: lifestyle, medications, and general secondary prevention.</s><s xml:id="_78Sa4dM">Hence, approximately one-third of the bank of messages were on lifestyle (diet, exercise, and smoking if relevant), with many of these from the TEXT ME study, <ref type="bibr" target="#b6">3</ref> another one-third of messages were on cardiovascular secondary preventative medications, and the remaining one-third of messages were on general secondary prevention topics (eg, BP or cholesterol targets, mental health, places and services providing help, and barriers to and facilitators of medication adherence).</s><s xml:id="_NUB7TQb">The medication messages included information on how medications worked, common side effects, and tips on taking medication regularly.</s><s xml:id="_YRZpnwA">Examples of messages include the following: "Antiplatelet meds (eg, clopidogrel) work with aspirin &amp; prevent blood clots &amp; decrease risk of repeat heart events, &lt;name&gt;, " and "Have you started new medications, &lt;name&gt;?</s><s xml:id="_bSm6Qam">Try to understand exactly what your medications do by talking with your Dr or pharmacist.</s><s xml:id="_fe6EndC">" Further messages are detailed in our previous study design article. <ref type="bibr" target="#b17">13</ref></s><s xml:id="_NeFFzwj">The program aimed to be suitable for low health literacy at the start but increased in complexity over the 12-month program.</s><s xml:id="_CKXggpM">A dedicated staff member, called a health counselor, based at the central coordinating center reviewed all responses from participants and responded to participants' replies from across Australia.</s><s xml:id="_WRpfYjK">Randomization was in a 1:1 allocation ratio stratified by site through a computerized randomization program.</s><s xml:id="_yNkTPac">A text message sent after hospital discharge to the patient informed the patient of his or her allocation.</s><s xml:id="_j8eygqt">The research team was blinded to treatment allocation and the participants were advised not to share their allocation information with the research team.</s><s xml:id="_ePd6FF5">The randomization program was connected to the software program delivering messages, hence minimizing data reentry or sharing of allocation information.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_HXpTJSa">Outcomes</head><p xml:id="_z8hNmcB"><s xml:id="_7ZYx6MW">Study visits were at baseline, 6 months by phone, and 12 months in person or by phone.</s><s xml:id="_3aWvsvY">The primary outcome was self-reported medication adherence to the 5 classes of medications indicated for secondary prevention after ACS.</s><s xml:id="_ESyrXTG">The 5 classes of medications were angiotensin-converting enzyme or angiotensin receptor blockers, Î²-blockers, statin lipid-lowering drugs, aspirin, and adenosine diphosphate receptor antagonists.</s><s xml:id="_qhAd9dB">Adherence was measured through asking participants to self-report on how many days in the past 30 days they missed a medication; this was asked for each of the 5 classes of medications at 2 separate time points (6 and 12 months).</s><s xml:id="_QNtgyWh">For the primary end point of self-reported medication adherence, patients were defined as adherent if at both 6 and 12 month time points the proportion of indicated medications taken was &gt;80% (&gt;24/30 days in the preceding 1 month) if not otherwise contraindicated.</s><s xml:id="_YGjYXPr">That is, to meet the primary outcome definition of adherence, data from 10 separate assessments of medical adherence were combined (5 medication classes each at 5 time points).</s><s xml:id="_dEfuF9y">Therefore, we would expect this calculation of overall adherence to give a lower measure of adherence compared with separate assessment of each medication's adherence.</s><s xml:id="_dNyj6tn">If patients reported a class of medication was contraindicated, then this was removed from the denominator.</s><s xml:id="_8skmqgS">To validate outcomes, we replicated this analysis using linked data from the PBS extract received on May 22, 2020.</s><s xml:id="_kC4EDaG">Adherence was defined as having purchased supply of 5 or more months separately over the 0-to 6-month and 6-to 12-month periods.</s><s xml:id="_Ta2enKJ">These data were obtained through extraction of linked data available from government repositories and with a separate participant consent.</s><s xml:id="_xPY3Jmx">The PBS is an Australian Government program that subsidizes medicines to make them more affordable and the PBS data set captures national information about prescription medications dispensed from community and hospital pharmacies.</s></p><p xml:id="_C5jNTQS"><s xml:id="_uT3Pbp8">Secondary outcomes were proportion of patients adherent to separate drug classes, LDL-C, systolic BP, diastolic BP, obesity (BMI and waist circumference), a composite of risk factor control (LDL-C &lt;1.8 mmol/L, BP &lt;140/90 mm Hg, exercising regularly [at least 5 days a week for â¥30 min/d of moderate activity], not smoking, and BMI &lt;25 kg/m 2 ), separate behavioral and psychosocial risk factors, cardiovascular events, hospitals readmissions, and all-cause mortality.</s><s xml:id="_BZd2Ya6">A formal end point adjudication process was implemented. <ref type="bibr" target="#b17">13</ref></s><s xml:id="_dpYkqV2">This comprised a Clinical End Point Adjudication Committee, consisting of independent specialist physicians with clinical and research expertise, adjudicating all potential clinical events according to predefined criteria.</s><s xml:id="_Th2EFRw">End point adjudicators were blinded to the patient's treatment group and were not provided with baseline characteristics.</s><s xml:id="_F6vQ9bN">Events were adjudicated by 2 clinically qualified and trained personnel independently, with disagreements reviewed by a third person.</s><s xml:id="_TypJxYx">The outcomes that underwent adjudication included cardiovascular deaths, noncardiovascular deaths, and undetermined cause of death and cardiovascular hospitalization occurring after registration (ie, signing informed consent) and within 30 days after termination of follow-up.</s><s xml:id="_U4rcpcg">We used linked Medicare Benefits Scheme data to examine health care service use and cost in intervention compared with control groups.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_9waVKNC">Statistical Analysis</head><p xml:id="_rVsgrkV"><s xml:id="_uBXbnZn">We considered a 10% improvement in medical adherence to be clinically meaningful.</s><s xml:id="_swaYgex">We estimated that to test for a 10% improvement in the primary outcome (relative risk [RR], 1.10) with 80% power in the treatment compared with the control arm (â70% adherence rising to 77%), we would require a total sample size of 1246.</s><s xml:id="_GenmU6F">A sample size of â1400 would account for 10% loss to follow-up and also enable a minimum detectable difference in secondary outcomes at 80% power of 0.15 mmol/L in LDL-C assuming an SD of 0.92 mmol/L, <ref type="bibr" target="#b20">16</ref> 2.7 mm Hg in systolic BP assuming an SD of 17 mm Hg, <ref type="bibr" target="#b20">16</ref> and a minimum detectable RR of 0.69 in cardiovascular events assuming a major cardiovascular event rate of 19%, or a power of approximately 13% to detect a RR of 0.80 in cardiovascular events assuming a lower cardiovascular event rate of 5% at 12 months from contemporary Australian data.</s></p><p xml:id="_uHxdcD5"><s xml:id="_8dVM7Cy">Analysis was performed according to the principles of intention to treat.</s><s xml:id="_9a5R3ck">The primary outcome was compared between groups using the Ï 2 test.</s><s xml:id="_3e3ATJU">The secondary continuous outcomes were analyzed using an analysis of covariance using the baseline values as the covariate and estimated mean difference.</s><s xml:id="_QQV8yf2">We used an analysis of covariance to compare treatments and to estimate the mean difference between treatments using least squares means methodology.</s><s xml:id="_72mu6yB">The model included treatment and baseline as fixed effects.</s><s xml:id="_HttEstK">No random effects were added.</s><s xml:id="_5qbuWcb">RRs are reported for dichotomous variables with corresponding 95% CIs and 2-sided P values.</s><s xml:id="_NJYJ2Uz">Effects across subgroups were examined using log-binomial regression models with treatment group, subgroup, and subgroup by treatment interaction as a fixed effect and center as random effect.</s><s xml:id="_YVX8xkE">Statistical significance was set at Î±=0.05.</s><s xml:id="_vNbwgwu">There were no interim analyses performed.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_U25epFv">RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_4PJGfgs">Characteristics of the Patients and Follow-Up</head><p xml:id="_HDfhSUd"><s xml:id="_S4evkS3">Between September 18, 2013, and February 16, 2017, a total of 3672 patients were approached and 1424 were recruited and randomized (2248 either did not meet eligibility criteria or refused to participate; Figure <ref type="figure">1</ref>).</s><s xml:id="_ReCME9g">At the conclusion of the study, 6 participants had withdrawn, 25 were unable to be contacted, and 15 had died.</s><s xml:id="_X3km3es">In the intervention group, 641 completed the intervention (did not reply stop and did not withdraw); 657 from the control group completed the intervention.</s><s xml:id="_gSxzabw">Of the intervention participants, 659/716 (92%) received at least 80% of the messages.</s><s xml:id="_xMTxVtE">Of all participants in both intervention and control groups, anthropometric measurements were measured by research staff in 892/1424 (63%) participants and the remainder were collected remotely by their general practitioner.</s></p><p xml:id="_qeg5SZ8"><s xml:id="_sRJTEAP">Data for the primary outcome of medication adherence at 6 and 12 months were available for 1379 (96.8% of randomized participants): 697 for the intervention group and 682 for the control group.</s><s xml:id="_QumCzwE">Medication adherence measures were available for 1368 (96.3%) of total participants at 6 months and 1287 (90.7%) at 12 months.</s><s xml:id="_NNNsXVE">The median time to follow-up was 12.5 months in the intervention group and 12.5 months in the control group.</s><s xml:id="_6UAVRwR">Mean participant age was 58.0Â±10.7 years and 20.8% were female.</s><s xml:id="_TdbxC4a">Baseline characteristics were similar between the groups (Table <ref type="table">1</ref>).</s></p><p xml:id="_Fc2cvS5"><s xml:id="_q8BhhBF">Use of guideline-recommended secondary prevention medications was high in both groups at baseline (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, 78.5%; aspirin, 98.8%; Î²-blockers, 87.0%; statins, 96.8%; and second antiplatelet agents, 86.6%;</s><s xml:id="_hKQXMdM">Table <ref type="table">1</ref>).</s><s xml:id="_tcdCGdS">At baseline, of 1424 patients enrolled, 16 (1.1%)</s><s xml:id="_aKrYHwD">had absolute contraindications to angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, 15 (1.1%) to aspirin, 55 (3.9%) to Î²-blockers, 9 (0.6%) to statins, and 17 (1.2%) to a second antiplatelet agent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_QujsFu9">Outcomes</head><p xml:id="_NVT4rMD"><s xml:id="_2tEE5MK">There was no significant difference in the primary end point of self-reported medical adherence to all recommended medications at 6 and 12 months between the intervention and control groups (RR, 0.93 [95% CI ARTICLE Circulation.</s><s xml:id="_zKHhE62">2022;145:1443-1455.</s><s xml:id="_vFT8HQy">DOI: 10.1161/CIRCULATIONAHA.121.056161</s><s xml:id="_6VFnrfG">May 10, 2022 1447 Chow et al Texts for Cardiovascular Disease Prevention 0.84-1.03];</s><s xml:id="_dvvhY9e">P=0.</s><s xml:id="_xYp23eV">15).</s><s xml:id="_RHhEJaY">There was also no significant difference in adherence to separate medications (Table <ref type="table" target="#tab_7">2</ref> and Figure <ref type="figure" target="#fig_0">2</ref>).</s><s xml:id="_6V5aPyW">The results were consistent when adjust-ing the threshold of medication adherence from &gt;80% to &gt;90%.</s><s xml:id="_RgDGHbC">Multiple imputation of missing data did not change the outcome (Table <ref type="table">S1</ref>).</s></p><p xml:id="_UBkePvf"><s xml:id="_s5kBUsw">3672 Patients assessed for eligibility 2248 Excluded 542 Did not own mobile phone 490 Not proficient in English 456 Declined to participate 760 Other 1424 Randomized 716 Randomized to receive text message intervention 708 Randomized to receive usual care 641 Completed intervention 75 Did not complete intervention 1 Withdrew consent 1 Did not meet criteria 54 Requested messages stop 20 No reason 11 Did not like the messages 8 Too many messages 5 Overseas 3 Unwell 3 Felt did not need messages 2 Busy lifestyle 2 Other reason 9 Unable to contact 10 Died during intervention period 657 Completed usual care 51 Did not complete usual care 5 Withdrew consent 21 Requested stop 16 Unable to contact 2 Moved 1 Unwell 1 No reason 5 Died during usual care period 697 Assessed at 12-month visit with: 653 Medication adherence measures 586 LDL-C measures 611 SBP measures 39 Did not complete 12-month assessment 1 Withdrew consent 1 Did not meet criteria 23 Responded stop 8 Unable to contact 6 Died before 12-month visit 682 Assessed at 12-month visit with: 634 Medication adherence measures 570 LDL-C measures 603 SBP measures 42 Did not complete 12-month assessment 3 Withdrew consent 17 Requested stop 16 Unable to contact 2 Moved 1 Unwell 3 Died before 12-month visit 716 Included in primary analysis 697 with complete data for primary analysis (19 missing adherence to number of recommended treatments at 6 or 12 months) 708 Included in primary analysis 682 with complete data for primary analysis (26 missing adherence to number of recommended treatments at 6 or 12 months) 713 Assessed at 6-month visit with: 692 Medication adherence measures 36 Did not complete 6-month assessment 31 Requested messages stop 1 Unable to contact 4 Died before 6-month visit 703 Assessed at 6-month visit with: 676 Medication adherence measures 9 Did not complete 6-month assessment 2 Withdrew consent 4 Requested stop 1 No reason 2 Died before 6-month visit Figure 1.</s><s xml:id="_UDNFqJB">Enrollment of participants in the TEXTMEDS randomized clinical trial.</s><s xml:id="_s4QxTWu">LDL-C indicates low-density lipoprotein cholesterol; SBP, systolic blood pressure; and TEXTMEDS, Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome.</s><s xml:id="_82qaKtE">Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on July 2, 2025 Table 1.</s><s xml:id="_VgPzmuQ">Baseline Characteristics Characteristics Control (n=708) Intervention (n=716) Total (n=1424)</s></p><p xml:id="_T457P6M"><s xml:id="_r7mbfdB">LDL-C, BP, BMI, and waist circumference were not statistically different between intervention and control groups at 12 months (Table <ref type="table" target="#tab_7">S2</ref>).</s><s xml:id="_WDFXEUJ">Regarding achieving recommended targets, participants were equally as likely to achieve LDL-C, BP, exercising regularly, and nonsmoking status, but significantly more participants in the intervention group reported achieving guidelinerecommended level of vegetable intake (RR, 1.90 [95% CI, 1.05-3.45];</s><s xml:id="_PyrT7Xk">P=0.035), fruit intake (RR, 1.15 [95% CI 1.03-1.29];</s><s xml:id="_78XW4cj">P=0.014), and BMI &lt;25 kg/m 2 (21.3% vs 18.0%; P=0.01; Table <ref type="table" target="#tab_7">2</ref> and Figure <ref type="figure" target="#fig_1">3</ref>).</s><s xml:id="_aRhjtt3">There was no difference in depression and anxiety scores but a slightly improved quality of life score (12-item short form survey, physical component score) for the intervention group (mean difference [95% CI], 1.1 [0.0,2.2];</s><s xml:id="_PGxvkat">P=0.045).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_7pxDCSB">Cardiovascular Events and Safety</head><p xml:id="_vM9xRDP"><s xml:id="_UZKFWJP">A list of clinically adjudicated cardiovascular events and serious adverse events is provided in Table <ref type="table">S3</ref>.</s><s xml:id="_h39nAJD">Incidence of any cardiovascular event was 17.9% versus 18.2% for the control and intervention groups, respectively, and there was no significant difference (RR, 1.02 [95% CI, 0.81-1.28];</s><s xml:id="_yA6ntNh">P=0.87; Table <ref type="table">S3</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_EMyqEvM">Medication Adherence Validation Using Linked PBS Data</head><p xml:id="_wGqJQyP"><s xml:id="_VFbkhNV">In total, 1379/1424 (96.8%) randomized participants had data on self-reported medical adherence; 1211/1424 (85.0%) had data on medical adherence using linked PBS data and 1179/1424 (82.8%) had overlapping data.</s><s xml:id="_McGSNUb">In the first 6 months, data from linked PBS suggest that patients have between 11.4% (second antiplatelet) and 19.6% (for Î²-blockers) less medication supply compared with self-reported medication adherence, with similar results between 6 and 12 months but with a greater gap: 13.1% for second antiplatelet agent and 31.7% for Î²-blockers.</s><s xml:id="_x7zNRGm">There was no significant difference in medications purchased by medication classes</s></p><p xml:id="_TQsMKDa"><s xml:id="_qAxWNM4">Table 1.</s><s xml:id="_4KGfTqR">Continued Characteristics Control (n=708) Intervention (n=716) Total (n=1424) Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on July 2, 2025</s></p><p xml:id="_fHAaqEz"><s xml:id="_XHAxTde">except for a small difference for second antiplatelet medication (Table <ref type="table">3</ref> and Figure <ref type="figure">S1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2h8cdJS">Health Care Service Use</head><p xml:id="_SzZkY7W"><s xml:id="_3w2w3jv">Valid consent and data for Medicare Benefits Scheme linkage was available for 1268 participants (89.0% of randomized patients).</s><s xml:id="_MqjZmmq">Use of medical services (general practitioner, specialist, mental and allied health, pathology, cardiac testing) and costs were similar between groups except for small differences in high-density lipoprotein cholesterol testing (mean number of high-density lipoprotein cholesterol checks per patient: 0.5 intervention versus 0.4 control; P=0.005 in 0 to 6 months) and *Groups were compared using a log-binomial regression including randomized groups (intervention/control) and corresponding baseline values as fixed effect.</s><s xml:id="_Q29eMMY">â Patients were defined as adherent if the proportion of indicated medications taken is &gt;80% at both time points on the basis of self-reported data (&gt;24/30 days at 6 months and &gt;24/30 days at 12 months) for the 5 guideline-recommended classes of medications if not otherwise contraindicated.</s><s xml:id="_hCVZ5g3">The denominator is the number randomized in each group minus those with contraindications and who completed 12 months of follow-up (withdrawals and true missings).</s></p><p xml:id="_xE8ZPSe"><s xml:id="_TCxvSu6">â¡Other comparisons use a 2Ã2 contingency</s></p><p xml:id="_bC97wmD"><s xml:id="_R3TA4J7">table, from which the relative risk and Ï 2 P value was extracted (no baseline values available).</s><s xml:id="_bpP5BsM">Â§Baseline values are dichotomous variables.</s><s xml:id="_fWnmFA3">â¥Baseline covariates are continuous.</s><s xml:id="_SZUP3wH">Â¶Participants who reported exercising 5 or more days per week Ã â¥30 min/d of moderate exercise.</s><s xml:id="_d5Jv9mn">#Includes former and nonsmokers.</s><s xml:id="_qDeqnvY">**Of LDL-C, BP, exercising regularly, nonsmoking status, and BMI &lt;25 kg/m 2 .</s><s xml:id="_95rXY2C">â  â Baseline value was the transformed 0 to 100 mental health score from baseline.</s><s xml:id="_uSsuQXG">â¡ â¡See Table S3 for a complete list of adjudicated cardiovascular events.</s><s xml:id="_bguC6hM">Â§ Â§ Reported as mean difference (95% confidence interval).</s><s xml:id="_WH4RwvN">Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on July 2, 2025 ORIGINAL RESEARCH ARTICLE Circulation.</s><s xml:id="_jm5VFVW">2022;145:1443-1455.</s><s xml:id="_BxHwMSv">DOI: 10.1161/CIRCULATIONAHA.121.056161</s><s xml:id="_r7Cg8fp">May 10, 2022 1451 Chow et al Texts for Cardiovascular Disease Prevention general practitioner visits (mean number of visits per patient: 4.7 intervention versus 5.3 control; P=0.01 in 6 to12 months; Tables <ref type="table">S4</ref> and <ref type="table">S5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_sVF4kPT">Process of Implementation Measures</head><p xml:id="_pMygTMP"><s xml:id="_43uAyWC">Among the 2248 patients who were screened but not randomized, the main reasons were that they did not own a mobile phone (542 [24%]), were not proficient in English (490 [22%]), or declined to participate (456 [20%]; Figure <ref type="figure">1</ref>).</s><s xml:id="_svHYNrA">After randomization, 54 participants receiving the intervention requested the text messages be stopped at varying times during the 12-month follow-up period and 1 withdrew consent.</s><s xml:id="_cnVbSDz">Reasons for stopping are listed in Figure <ref type="figure">1</ref>.</s><s xml:id="_WnxSTHR">There were 2737 text message replies from participants; 57% (1661) did not require a reply from the health counselor and 95% (2737) took the health counselor &lt;5 minutes to process or respond to.</s><s xml:id="_B3NMAdc">Only 1 message required rapid clinical escalation because it reported chest pain.</s></p><p xml:id="_zwdpHQn"><s xml:id="_gY6UD6J">A total of 509 (401 male) of the 716 intervention participants (response rate of 71%) responded to the TEXTMEDS user feedback survey.</s><s xml:id="_tkVmCMR">Most people either agreed or strongly agreed that the text message program was useful (438/509 [86%]), was easy to understand (476/509 [94%]), reminded them to take their regular medications (323/509 [63%]), and motivated them to change their lifestyle (323/509 [63%]; Table <ref type="table">S6</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ZRNGBre">DISCUSSION</head><p xml:id="_jgDGkfa"><s xml:id="_pxZWQm2">Provision of consistent education and support on prevention after discharge after ACS remains an implementation challenge for many health services and systems.</s><s xml:id="_bQdmW9B">In the TEXTMEDS study, we implemented a customized text message-based program requiring minimal central staff support for 1 year for patients discharged from Patients were defined as adherent if the proportion of indicated medications taken was &gt;80% at both time points (&gt;24/30 days at 6 months and &gt;24/30 days at 12 months) for each individual medication class and for the primary end point of self-reported medical adherence for all 5 guideline-recommended classes of medications at both 6 and 12 months, unless contraindicated.</s><s xml:id="_VfBg3eU">ACE angiotensin-converting enzyme; ARB, angiotensin receptor blocker; and TEXTMEDS, Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome.</s><s xml:id="_jwDqm6t">Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on July 2, 2025 18 urban or rural centers in Australia in a multicenter RCT.</s><s xml:id="_7sCyMEn">The study found no significant effect on the primary outcome of medication adherence by self-report or on exploratory analyses through pharmaceutical dispensation data.</s><s xml:id="_Dzr55Km">There was no effect on objective measures including LDL-C, weight, waist circumference, or BP.</s><s xml:id="_eWVnN56">Similar to a previous trial using a similar intervention, intervention participants were more likely to eat guideline-recommended servings of fruit and vegetables.</s><s xml:id="_jzME4j2">The intervention was safe and did not increase, and may have decreased, health care use.</s></p><p xml:id="_ABUzAhP"><s xml:id="_WsYgu2r">There was no significant effect on the primary outcome measure of medical adherence to 5 medication classes, but this study was powered to detect a difference of &gt;10%, which we had hypothesized to be clinically meaningful.</s><s xml:id="_wYCKXSz">To help put the results in context, an RR of 0.93 for our primary outcome (7% difference) would need a sample size of â9000 to have â90% to detect this difference.</s><s xml:id="_pCMJNma">There is no consensus on assessing medical adherence and pragmatism and accuracy usually need to be balanced in deciding on the best approach.</s><s xml:id="_JXeBcAk">Adherence is usually reported as a percentage of the prescribed dose taken over a specified time period, but there is no consensus over what constitutes adequate adherence and methods used to measure adherence vary between studies. <ref type="bibr" target="#b21">17</ref></s><s xml:id="_Xr634j9">In this study, we validated the self-reported medication adherence approach taken in the study with concurrent linked data from the PBS, which is a comprehensive data source for all prescribed medications in Australia.</s><s xml:id="_sYMgce9">We confirmed no significant difference in medication adherence but also demonstrated that self-reported adherence appeared to systematically overestimate prescription refill-confirmed adherence.</s><s xml:id="_KtCggJ6">Self-reported medication adherence questionnaires are convenient, inexpensive, and easy to administer, can provide an immediate assessment of adherence, and is the method that most reflects clinical practice.</s><s xml:id="_y85JydP">However, self-report is susceptible to recall and acceptability bias.</s><s xml:id="_5JT6XRD">Furthermore, the variety in self-reported methods used to assess medication adherence in research can introduce significant heterogeneity between clinical trials, <ref type="bibr" target="#b22">18</ref> which makes comparisons difficult.</s><s xml:id="_mkycuWz">Objective quantifiable measures of medication adherence, such as pill counts and prescription refill rates, may be more reliable.</s><s xml:id="_689WVAs">Although these measures appear simple and objective, they assume that supply equates to ingestion.</s></p><p xml:id="_QhR6rSe"><s xml:id="_xKvEm5V">We also found that despite our messages having relatively fewer lifestyle-focused texts and more medication adherence texts compared with our previous programs, <ref type="bibr" target="#b23">[19]</ref><ref type="bibr" target="#b24">[20]</ref><ref type="bibr" target="#b25">[21]</ref><ref type="bibr" target="#b26">[22]</ref> intervention participants were still more likely to report adherence to healthy lifestyle practices than to have better medication adherence.</s><s xml:id="_g6hzQ6F">A possible explanation is that there are external factors affecting intentional (eg, cost) and nonintentional (eg, forgetfulness) medication adherence that were not possible to address with TEXTMEDS.</s><s xml:id="_qaTfjxN">These include social and economic factors such as medication costs, <ref type="bibr" target="#b27">23</ref> patient-doctor relationship, <ref type="bibr" target="#b28">24,</ref><ref type="bibr" target="#b29">25</ref> fixed health beliefs, <ref type="bibr" target="#b30">26</ref> belonging to an ethnic minority, depression, and reduced social support. <ref type="bibr" target="#b31">27</ref></s><s xml:id="_SWVZX5e">n addition, side effects, <ref type="bibr" target="#b32">28</ref> pill burden/treatment complexity, <ref type="bibr" target="#b33">29</ref> and treatment of asymptomatic disease <ref type="bibr" target="#b34">30</ref> can adversely affect adherence and are more difficult to target with mobile health methods.</s><s xml:id="_7zjZzzh">Other possible reasons for no significant effect on medical adherence is that these patients were enrolled soon after discharge and in this setting medical adherence is usually good and hence there is limited room for improvement.</s><s xml:id="_u7kZxEp">There also is a possibility that an intervention on healthy lifestyles may give patients a feeling that if they have a healthy lifestyle they can take fewer medications.</s><s xml:id="_EHMc65h">Many major pharmacy groups in Australia offer a complimentary text message (or app-based) prescription reminder service, which may have reduced the chances of finding a significant difference between intervention and control groups.</s><s xml:id="_NehnDAt">We did not acquire data on the proportion of patients who used this or other text message reminder services.</s><s xml:id="_7UBNAnx">In contrast, these external factors may be less applicable to lifestyle behavior change and thus more easily targeted with text messaging, as has been seen in previous studies. <ref type="bibr" target="#b7">4</ref></s><s xml:id="_APeFaQB">TEXT ME showed a greater effect on lifestyle risk factors including improvement of LDL-C and BP compared with TEXTMEDS; however, the TEXT ME and TEXTMEDS programs are fundamentally different.</s><s xml:id="_UJ9QCqh">Although we used some lifestyle-focused messages from TEXT ME, the medication adherence context was expanded and the lifestyle content was not the main focus.</s></p><p xml:id="_qteHvtc"><s xml:id="_Cnbttht">Our findings differ from a meta-analysis of 16 RCTs assessing text messaging for medication adherence</s></p><p xml:id="_HZjxfNZ"><s xml:id="_a3UfbdX">Table 3. Pharmaceutical Benefits Scheme Validation of Adherence Compared With Self-Report for Each Medication Class* Over the First and Second 6 Months of the Intervention â  Treatment group Total P value Control Intervention ACEI/ARB adherence 0 to 6 months PBS â¡ 386/480 (80.4) 375/460 (81.5) 761/940 (81.0) 0.67 6 to 12 months PBS Â§ 340/431 (78.9) 327/411 (79.6) 667/842 (79.2) 0.81 0 to 6 months self to report â¡â¥ 402/408 (98.5) 386/394 (98.0) 788/802 (98.3) 0.55 6 to 12 months self to report Â§â¥ 347/353 (98.3) 328/342 (95.9) 675/695 (97.1) 0.06 Î²-blocker adherence 0 to 6 months PBS â¡ 398/502 (79.3) 394/509 (77.4) 792/1011 (78.3) 0.47 6 to 12 months PBS Â§ 284/435 (65.3) 292/447 (65.3) 576/882 (65.3) 0.99 0 to 6 months self-report â¡â¥ 408/417 (97.8) 423/432 (97.9) 831/849 (97.9) 0.94 6 to 12 months self-report Â§â¥ 331/343 (96.5) 350/359 (97.5) 681/702 (97.0) 0.44 Statin adherence 0 to 6 months PBS â¡ 475/578 (82.2) 480/589 (81.5) 955/1167 (81.8) 0.76 6 to 12 months PBS Â§ 433/552 (78.4) 427/559 (76.4) 860/1111 (77.4) 0.41 0 to 6 months self-report â¡â¥ 520/529 (98.3) 526/537 (98.0) 1,046/1066 (98.1) 0.68 6 to 12 months self-report Â§â¥ 465/474 (98.1) 462/477 (96.9) 927/951 (97.5) 0.22 Second antiplatelet months of supply purchased 0 to 6 months PBS â¡ 461/517 (89.2) 436/515 (84.7) 897/1032 (86.9) 0.03 6 to 12 months PBS Â§ 399/478 (83.5) 389/468 (83.1) 788/946 (83.3) 0.88 0 to 6 months self-report â¡â¥ 447/455 (98.2) 446/453 (98.5) 893/908 (98.3) 0.80 6 to 12 months self-report Â§â¥ 314/325 (96.6) 294/306 (96.1) 608/631 (96.4) 0.72 Values are n (%).</s><s xml:id="_BJGgkmH">ACEI indicates angiotensin-converting enzyme inhibitor; and ARB, angiotensin receptor blocker.</s><s xml:id="_kFS7TzR">*Aspirin was not included in this analysis because this medication does not require a prescription.</s></p><p xml:id="_7EuwyJn"><s xml:id="_B6dQQMq">â Pharmaceutical Benefits Scheme (PBS) validation of adherence was determined by assessing months of supply, which was calculated as (dosage per day stated at 6 or 12 months/dosage per tablet) Ã (maximum quantity/28).</s><s xml:id="_WHr3U5c">When a patient's dosage per day stated at baseline was not available, we assumed 1 refill is a 1-month supply, except for metoprolol tartrate (3.2 months).</s><s xml:id="_vgQCQV3">Adherence was defined as having purchased supply of 5 or more months separately over the 0 to 6 months and 6 to 12 months periods.</s></p><p xml:id="_26DVjzc"><s xml:id="_w5WtWHA">â¡Denominator is the number of patients self-reporting that they have been prescribed the medication and with PBS records available over the first 6 months of the intervention.</s></p><p xml:id="_hrYdxZC"><s xml:id="_dRmHCFa">Â§Denominator is the number of patients self-reporting that they have been prescribed the medication who have not indicated they have stopped taking it at 6 months and with PBS records available over the second 6 months of the intervention.</s></p><p xml:id="_N2fMS4U"><s xml:id="_BSeetVj">â¥Self-reported adherence was defined as taking medication for &gt;24 days out of the previous 30 days at 6 or 12 months.</s><s xml:id="_m7dXEHa">The denominator excludes participants for whom adherence by self-report was missing.</s><s xml:id="_4UDrTrG">Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on July 2, 2025 in adults with chronic disease.</s><s xml:id="_pBFD8sy">This showed that in a pooled analysis of 2742 patients, participants receiving text messages were more than twice as likely to adhere to medications (OR, 2.11 [95% CI, 1.52-2.93];</s><s xml:id="_q584ysu">P&lt;0.001). <ref type="bibr" target="#b16">12</ref></s><s xml:id="_Ectp8Fb">However, there was significant heterogeneity between studies, median sample size was small (97 participants [range, 21-538]), and the median intervention duration was short (12 weeks [range, 4-48]).</s><s xml:id="_tuFQFjE">In contrast, TEXTMEDS included patients with recent ACS (which may represent more motivated patients because of the recent event as well as being eager to enroll in a clinical trial), had a significantly larger sample size than the individual studies across 15 sites in Australia, and had long-term follow-up.</s><s xml:id="_JFWwzkH">Median age was also low compared with TEXTMEDS (39 vs 58 years) and the included studies evaluated various chronic diseases, with only 5 of the 16 assessing cardiovascular disease.</s><s xml:id="_qsJVMrm">A recent systematic review showed that younger and older patients may have higher rates of nonadherence compared with middle-aged adults. <ref type="bibr" target="#b31">27</ref></s><s xml:id="_x53b45F">ost new technologies introduced into health care increase overall patient costs, but here the linked data analysis found no increased costs and fewer general practitioner visits and some cardiac tests.</s><s xml:id="_8WpZ5PU">The finding is consistent with the cost savings demonstrated in previous text message-based intervention programs, <ref type="bibr" target="#b14">11</ref> suggesting that the overall costs of health care use do not increase with implementation of this digital health program, but this needs to be formally evaluated in a costeffectiveness analysis.</s></p><p xml:id="_8zTkKmb"><s xml:id="_5T6UTN4">The process of implementation evaluation that complemented this study demonstrates the technical success in implementation of this program across Australia.</s><s xml:id="_kujEeWr">The implementation also demonstrates that providing unified messaging that is perceived helpful by patients improves the patient experience and engenders feelings of support after ACS using a low-cost technology intervention.</s><s xml:id="_jPCsXwa">Further iterations of the program and generations of smartphones have increased the ability for the quality of the content to be enriched with images and videos and not limiting accessibility to participants through existing mobile networks.</s><s xml:id="_FTAuXp2">The descriptive analyses of TEXTMEDS indicated that participants were engaged in the program, with a high number of responses to messages and good overall feedback with respect to program acceptability and perceived usefulness.</s><s xml:id="_FXMTvVP">Separate analyses indicated that supportive and informational messages in particular elicited more message replies. <ref type="bibr" target="#b35">31</ref></s><s xml:id="_npRNPVD">here are several limitations to our study that need to be considered.</s><s xml:id="_QJc2DJz">The study intervention, although evaluated in a randomized design, was not able to be blinded.</s><s xml:id="_hwEPeZt">The primary outcome was self-reported, although there was validation of the primary outcome performed among those who consented to the linked data for medications.</s><s xml:id="_Gc58KRN">Participation in a clinical trial could have caused people in both arms to be more adherent to their medicines.</s></p><p xml:id="_rf7HBGX"><s xml:id="_mM6ZF2F">We did not assess baseline medical adherence because many participants would not have been on the secondary prevention medications for 30 days at the time of recruitment.</s><s xml:id="_BpFdRAr">There was evidence of cultural diversity in the study population, but only one-fifth of the participants were women, which is consistent with other studies of patients with ACS.</s><s xml:id="_YH27bkQ">The pathology results used in secondary outcome assessments were those drawn from routine care and hence were not centralized and the dates of the tests were unable to be strictly stipulated by study staff because the study had a limited budget and did not include costs of study bloodwork.</s><s xml:id="_aAJeKkK">The study sites represent a broad range of sites across urban and rural Australia and included a culturally diverse population.</s><s xml:id="_Q8B8FEw">There was good consistency with respect to the outcomes and findings in terms of overall acceptability of messaging across major regions.</s><s xml:id="_mJ4qzDP">This suggests the findings are likely to be generalizable to other regions.</s><s xml:id="_mxZUMfN">Ongoing studies are assessing whether digital health interventions for medication adherence would be effective in different chronic diseases, including heart failure and diabetes. <ref type="bibr" target="#b36">32</ref></s><s xml:id="_BUmSRCT">he TEXTMEDS text message-based program to provide education and support to patients with ACS was feasible to implement across 18 centers and 3 time zones in Australia.</s><s xml:id="_YMFAXuN">The program implementation was not associated with increases in the primary outcome of medical adherence, measured by self-report or linkage to medication dispensing, or changes in LDL-C or BP control.</s><s xml:id="_XqgXVV2">Whether customized and personalized text message-based education and support prevention programs offer a means of delivering consistent education and support to patients after hospitalization for acute cardiac events remains uncertain.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 2 .</head><label>2</label><figDesc><div><p xml:id="_FuHuxNz"><s xml:id="_uFDQYGr">Figure 2. Medication adherence at 6 and 12 months for intervention and control in the TEXTMEDS randomized clinical trial.</s><s xml:id="_GxXs8XE">Patients were defined as adherent if the proportion of indicated medications taken was &gt;80% at both time points (&gt;24/30 days at 6 months and &gt;24/30 days at 12 months) for each individual medication class and for the primary end point of self-reported medical adherence for all 5 guideline-recommended classes of medications at both 6 and 12 months, unless contraindicated.</s><s xml:id="_w7srXfb">ACE angiotensin-converting enzyme; ARB, angiotensin receptor blocker; and TEXTMEDS, Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome.</s><s xml:id="_XJRBCtU">Downloaded from http://ahajournals.org by on July 2, 2025</s></p></div></figDesc><graphic coords="9,57.90,66.77,469.20,346.32" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 3 .</head><label>3</label><figDesc><div><p xml:id="_fkZBM6x"><s xml:id="_6QrfTzY">Figure 3. Cardiovascular risk factor outcomes for intervention and control in the TEXTMEDS randomized clinical trial.</s><s xml:id="_JEzUfcU">BMI indicates body mass index; BP, blood pressure; LDL-C, low-density lipoprotein cholesterol; and TEXTMEDS, Text Messages to Improve Medication Adherence and Secondary Prevention After Acute Coronary Syndrome.</s><s xml:id="_46hDsA5">Downloaded from http://ahajournals.org by on July 2, 2025</s></p></div></figDesc><graphic coords="10,57.90,66.76,469.20,300.60" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_7"><head>Table 2 . Primary and Secondary End Point Analyses at 6 and 12 Months of Follow-Up*</head><label>2</label><figDesc><div><p xml:id="_2TWKGTG"><s xml:id="_KmvrFTp">General Anxiety Disorder-7; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MCS, Mental Component Summary; MET, metabolic equivalent task; PCS, Physical Component Summary; PHQ-9, Patient Health Questionnaire-9; RR, relative risk; and SF-12, 12-item short form survey.</s></p></div></figDesc><table><row><cell>Measure</cell><cell>Control (n=708)</cell><cell>Intervention (n=716)</cell><cell>RR (95% CI)</cell><cell>P value</cell></row><row><cell>Primary end point â </cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Self-reported adherence to all 5 medica-</cell><cell>370/682 (54.3)</cell><cell>351/697 (50.4)</cell><cell>0.93 (0.84, 1.03)</cell><cell>0.148</cell></row><row><cell>tion classes at 6 and 12 months â¡</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Secondary end points</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">Adherence to each medication class at 6 and 12 months â¡</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Aspirin</cell><cell>613/638 (96.1)</cell><cell>646/671 (96.3)</cell><cell>1.00 (0.98, 1.02)</cell><cell>0.856</cell></row><row><cell>Î²-blocker</cell><cell>486/581 (83.6)</cell><cell>516/613 (84.2)</cell><cell>1.01 (0.96, 1.06)</cell><cell>0.804</cell></row><row><cell>ACEI/ARB</cell><cell>498/621 (80.2)</cell><cell>489/636 (76.9)</cell><cell>0.96 (0.90, 1.02)</cell><cell>0.154</cell></row><row><cell>Statin</cell><cell>624/655 (95.3)</cell><cell>632/668 (94.6)</cell><cell>0.99 (0.97, 1.02)</cell><cell>0.586</cell></row><row><cell>Second antiplatelet</cell><cell>533/632 (84.3)</cell><cell>532/636 (83.6)</cell><cell>0.99 (0.95, 1.04)</cell><cell>0.739</cell></row><row><cell>LDL-C &lt;1.8 mmol/L Â§</cell><cell>267/570 (46.8)</cell><cell>281/586 (48.0)</cell><cell>1.01 (0.90, 1.14)</cell><cell>0.824</cell></row><row><cell>BP &lt;140/90 mm Hg Â§</cell><cell>445/603 (73.8)</cell><cell>436/611 (71.4)</cell><cell>0.96 (0.90, 1.02)</cell><cell>0.205</cell></row><row><cell>Exercising regularlyâ¥ Â¶</cell><cell>405/596 (68.0)</cell><cell>432/610 (70.8)</cell><cell>1.02 (0.96, 1.09)</cell><cell>0.523</cell></row><row><cell>Total physical activity, MET min/wkâ¥</cell><cell>3246.9 (2851.7, 3642.1)</cell><cell>3047.0 (2657.6, 3436.3)</cell><cell>-199.92 (-754.72, 354.89) Â§ Â§</cell><cell>0.480</cell></row><row><cell>Nonsmokerâ¥#</cell><cell>520/613 (84.8)</cell><cell>528/636 (83.0)</cell><cell>1.00 (0.97, 1.02)</cell><cell>0.971</cell></row><row><cell>BMI &lt;25 kg/m Â§</cell><cell>110/581 (18.9)</cell><cell>138/583 (23.7)</cell><cell>1.19 (1.04, 1.35)</cell><cell>0.011</cell></row><row><cell>HDL-C &gt; 1 mmol/L Â§</cell><cell>320/580 (55.2)</cell><cell>334/594 (56.2)</cell><cell>1.00 (0.93, 1.09)</cell><cell>0.912</cell></row><row><cell>â¥5 vegetable servings per day Â§</cell><cell>16/597 (2.7)</cell><cell>33/610 (5.4)</cell><cell>1.90 (1.05, 3.45)</cell><cell>0.035</cell></row><row><cell>â¥2 fruit servings per day Â§</cell><cell>222/597 (37.2)</cell><cell>242/610 (39.7)</cell><cell>1.15 (1.03, 1.29)</cell><cell>0.014</cell></row><row><cell>Achieving all 5 key guideline levels Â§**</cell><cell>21/506 (4.2)</cell><cell>32/505 (6.3)</cell><cell>1.40 (0.84, 2.34)</cell><cell>0.191</cell></row><row><cell>Achieving â¥4 key guideline levels Â§</cell><cell>157/506 (31.0)</cell><cell>174/505 (34.5)</cell><cell>1.12 (0.95, 1.33)</cell><cell>0.175</cell></row><row><cell>Achieving â¥3 key guideline levels Â§</cell><cell>349/506 (69.0)</cell><cell>351/505 (69.5)</cell><cell>1.01 (0.94, 1.09)</cell><cell>0.779</cell></row><row><cell>PHQ-9 total score</cell><cell>3.8 (3.5, 4.2)</cell><cell>3.7 (3.4, 4.1)</cell><cell>-0.1 (-0.6, 0.4) Â§ Â§</cell><cell>0.700</cell></row><row><cell>Depressed (PHQ-9 &gt;14) â  â </cell><cell>30/595 (5.0)</cell><cell>29/609 (4.8)</cell><cell>0.93 (0.57, 1.50)</cell><cell>0.750</cell></row><row><cell>GAD-7 total scoreâ¥</cell><cell>3.5 (3.2, 3.9)</cell><cell>3.6 (3.3, 3.9)</cell><cell>0.06 (-0.42, 0.55) Â§ Â§</cell><cell>0.800</cell></row><row><cell>Not anxious (GAD-7 &lt;5)</cell><cell>429/596 (72.0)</cell><cell>423/606 (69.8)</cell><cell></cell><cell></cell></row><row><cell>SF-12: PCS*</cell><cell>46.5 (45.7, 47.2)</cell><cell>47.6 (46.8, 48.3)</cell><cell>1.1 (0.0, 2.2) Â§ Â§</cell><cell>0.045*</cell></row><row><cell>SF-12: MCS*</cell><cell>51.9 (51.1, 52.7)</cell><cell>51.2 (50.4, 52.0)</cell><cell>-0.7 (-1.8, 0.4) Â§ Â§</cell><cell>0.204</cell></row><row><cell>Major adverse cardiovascular event â¡ â¡ â¡</cell><cell>122/681 (17.9)</cell><cell>127/696 (18.2)</cell><cell>1.02 (0.81, 1.28)</cell><cell>0.873</cell></row><row><cell cols="5">Values are n (%) or mean (95% CI). ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pres-</cell></row><row><cell>sure; GAD-7,</cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_ewW8EdR"><s xml:id="_xP6q3Be">May 10, 2022 Circulation.</s><s xml:id="_H6XPuYm">2022;145:1443-1455.</s><s xml:id="_FaXycXp">DOI: 10.1161/CIRCULATIONAHA.121.056161</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p xml:id="_rU5QFx5"><s xml:id="_tQeMgjY">Downloaded from http://ahajournals.org by on July 2, 2025</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div xml:id="_m2V23wP"><p xml:id="_sfm6rR2"><s xml:id="_XymztZn"><rs type="institution">Medicine and Health (J</rs><rs type="person">.R., R.B., M.A.F., M.M.</rs>), and <rs type="funder">ANZAC Research Institute (D</rs><rs type="person">.B.</rs>), <rs type="institution">University of Sydney, Australia</rs>.</s><s xml:id="_Kpa4DeP"><rs type="institution">Department of Cardiology, Westmead Hospital, Sydney, Australia (C</rs><rs type="person">.K.C.</rs>, <rs type="person">H.K.</rs>, <rs type="person">A.T.</rs>).</s><s xml:id="_MwX7v3Q"><rs type="institution">University of Western Australia, Perth</rs> (<rs type="person">G.S.H.</rs>, <rs type="person">P.T.</rs>).</s><s xml:id="_urrh2eW"><rs type="affiliation">Department of Cardiology, Royal Perth Hospital, Australia</rs> (<rs type="person">G.S.H.</rs>).</s><s xml:id="_dctrVKq"><rs type="affiliation">Department of Cardiology, Royal Brisbane and Women's Hospital, Brisbane, Australia</rs> (<rs type="person">J.A.</rs>).</s><s xml:id="_knvQSAU">The <rs type="affiliation">University of Queensland, Brisbane, Australia</rs> (<rs type="person">J.A.</rs>, <rs type="person">C.H.C.</rs>).</s><s xml:id="_978BUAM"><rs type="affiliation">Department of Cardiology, Royal North Shore Hospital, Sydney, Australia</rs> (<rs type="person">R.B.</rs>).</s><s xml:id="_MgQWbVy"><rs type="affiliation">College of Medicine and Public Health, Flinders University, Adelaide, South Australia</rs> (<rs type="person">D.P.C.</rs>, <rs type="person">N.K.</rs>).</s><s xml:id="_RasYqj2"><rs type="affiliation">Hunter Medical Research Institute, Newcastle, Australia (N.C.</rs>).</s><s xml:id="_HsJ2fAS"><rs type="affiliation">Faculty of Medicine, The University of New South Wales, Sydney, Australia (C.</rs><rs type="person">J.</rs>).</s><s xml:id="_s9nwNHA"><rs type="affiliation">Department of Cardiology, Liverpool Hospital, Sydney, Australia (C.</rs><rs type="person">J.</rs>).</s><s xml:id="_bGMxddz"><rs type="affiliation">Department of Cardiology, Royal Darwin Hospital, Darwin, Australia</rs> (<rs type="person">N.K.</rs>).</s><s xml:id="_cTd9t6w"><rs type="affiliation">Menzies School of Health Research, Darwin, Australia</rs> (<rs type="person">N.K.</rs>).</s><s xml:id="_TBYvsBN"><rs type="affiliation">Allied Health Department, Fiona Stanley Hospital, Perth, Australia (A.</rs><rs type="person">M.</rs>).</s><s xml:id="_mWyDfQ7"><rs type="affiliation">School of Allied Health, Curtin University, Perth, Australia (A.M.</rs>).</s><s xml:id="_EvYhbat"><rs type="affiliation">Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia</rs> (<rs type="person">M.M.</rs>).</s><s xml:id="_JTb5DG6"><rs type="affiliation">Department of Cardiology, Sunshine Coast University Hospital, Brisbane, Australia</rs> (<rs type="person">R.P.</rs>).</s><s xml:id="_J2RkyNt"><rs type="affiliation">Department of Cardiology, Wollongong and Shellharbour Hospitals, Wollongong, Australia</rs> (<rs type="institution">P.S.</rs>).</s><s xml:id="_2pqRzqa"><rs type="affiliation">Coffs Cardiology, Coffs Harbour, Australia</rs> (<rs type="person">J.W.</rs>).</s><s xml:id="_cyWCuPA"><rs type="affiliation">Department of Cardiology, Prince Charles Hospital, Brisbane, Australia (C.</rs><rs type="person">H.C.</rs>).</s><s xml:id="_Vqgtz2Q"><rs type="affiliation">Department of Cardiology, Sir Charles Gairdner Hospital, Perth, Australia</rs> (<rs type="person">P.T.</rs>).</s><s xml:id="_DJy2r3k"><rs type="affiliation">Harry Perkins Institute of Medical Research, Perth, Australia</rs> (P.T.).</s><s xml:id="_e89Tjgt">The <rs type="affiliation">George Institute for Global Health, Sydney, Australia</rs> (C.K.C., H.K., A.R., G.S.H., S.S., A.R.).</s><s xml:id="_6t5MKcu">Downloaded from <ref type="url" target="http://ahajournals.org">http://ahajournals.org</ref> by on July 2, 2025</s></p></div>
			</div>
			<listOrg type="funding">
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_dMDRPWs">ARTICLE INFORMATION</head><note type="other" xml:id="_zhtF3jC">Received</note></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ddfYE7y">Disclosures</head><p xml:id="_sFp3uca"><s xml:id="_xDYXCjJ">None.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_GBwP8Pu">Supplemental Material</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_vPNUMBy">TEXTMEDS investigator list</head><p xml:id="_dDFHF6p"><s xml:id="_XmKTyPM">Tables S1-S6</s></p><p xml:id="_T3PKvVT"><s xml:id="_UerFqjG">Figure <ref type="figure">S1</ref></s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title/>
		<idno type="DOI">10.4324/9780203005217-19</idno>
		<idno>199/715 (27.8) 409/1420 (28.8</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tzxcw8s">Age</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">0</biblScope>
			<biblScope unit="page">58</biblScope>
		</imprint>
	</monogr>
	<note>0 (10.4) 58.0 (10.7) Men Aboriginal/Torres Strait (3.7) South Asian 36/708 (5.1) 40/716 (5.6) 76/1424 (5.3) Other Asian 32/708 (4.5) 19/716 (2.7) 51/1424 (3.6) Arab 22/708 (3.1) 16/716 (2.2) 38/1424 (2.7) Black African 2/708 (0.3) 1/716 (0.1) 3/1424 (0.2) Sub-Saharan African 1/708 (0.1) 1/716 (0.1) 2/1424 (0.1) Other* 38/708 (5.4) 25/716 (3.5) 63/1424 (4.4) Marital status Single 116/708 (16.4) 102/716 (14.2) 218/1424 (15.3) Married 426/708 (60.2) .7) Highest formal education None 4/705 (0.6) 1/715 (0.1) 5/1420 (0.4) Primary school 47/705 (6.7) 49/715 (6.9) 96/1420 (6.8) Year 10 (school certificate) 210/705 (29.8) ) Year 12 (higher school certificate) 121/705 (17.2) 122/715 (17.1</note>
	<note type="raw_reference">Age, y 58.0 (10.9) 58.0 (10.4) 58.0 (10.7) Men 559/708 (79.0) 569/716 (79.5) 1128/1424 (79.2) Race/ethnicity Caucasian 552/708 (78.0) 587/716 (82.0) 1139/1424 (80.0) Aboriginal/Torres Strait Islander 25/708 (3.5) 27/716 (3.8) 52/1424 (3.7) South Asian 36/708 (5.1) 40/716 (5.6) 76/1424 (5.3) Other Asian 32/708 (4.5) 19/716 (2.7) 51/1424 (3.6) Arab 22/708 (3.1) 16/716 (2.2) 38/1424 (2.7) Black African 2/708 (0.3) 1/716 (0.1) 3/1424 (0.2) Sub-Saharan African 1/708 (0.1) 1/716 (0.1) 2/1424 (0.1) Other* 38/708 (5.4) 25/716 (3.5) 63/1424 (4.4) Marital status Single 116/708 (16.4) 102/716 (14.2) 218/1424 (15.3) Married 426/708 (60.2) 429/716 (59.9) 855/1424 (60.0) Separated 91/708 (12.9) 87/716 (12.2) 178/1424 (12.5) Widowed 29/708 (4.1) 35/716 (4.9) 64/1424 (4.5) De facto 46/708 (6.5) 63/716 (8.8) 109/1424 (7.7) Highest formal education None 4/705 (0.6) 1/715 (0.1) 5/1420 (0.4) Primary school 47/705 (6.7) 49/715 (6.9) 96/1420 (6.8) Year 10 (school certificate) 210/705 (29.8) 199/715 (27.8) 409/1420 (28.8) Year 12 (higher school certificate) 121/705 (17.2) 122/715 (17.1) 243/1420 (17.1) Diploma/technical college 176/705 (25.0) 183/715 (25.6) 359/1420 (25.3) University undergraduate 84/705 (11.9) 89/715 (12.4) 173/1420 (12.2) University postgraduate 63/705 (8.9) 72/715 (10.1) 135/1420 (9.5) Employment status Working full time 342/707 (48.4) 351/715 (49.1) 693/1422 (48.7) Working part time 82/707 (11.6) 78/715 (10.9) 160/1422 (11.3) Unemployed (not disabled) 37/707 (5.2) 39/715 (5.5) 76/1422 (5.3) Unemployed (disabled) 33/707 (4.7) 38/715 (5.3) 71/1422 (5.0) Retired 198/707 (28.0) 192/715 (26.9) 390/1422 (27.4) Never worked 1/707 (0.1) 3/715 (0.4) 4/1422 (0.3) Homemaker 14/707 (2.0) 14/715 (2.0) 28/1422 (2.0) BMI, kg/m 2 29.5 (5.5) 28.9 (5.5) 29.2 (5.5) BMI &gt;25 kg/m 2 555/703 (78.9) 535/706 (75.8) 1090/1409 (77.4) Waist circumference, cm 104.5 (14.0) 103.4 (15.7) 104.0 (14.9) Hip circumference, cm 105.0 (12.3) 104.1 (13.3) 104.6 (12.8) Blood pressure, mm Hg 123(16)/73 (11) 123 (15)/73 (10) 123 (16)/73 (10) SBP &gt;140 mm Hg or DBP &gt;90 mm Hg 120/708 (16.9) 90/713 (12.6) 210/1421 (14.8) Heart rate, bpm 70.7 (11.3) 70.5 (11.7) 70.6 (11.5) Total cholesterol, mmol/L 4.8 (1.5) 4.7 (1.2) 4.7 (1.4) Total cholesterol &gt;4 mmol/L 439/658 (66.7) 456/661 (69.0) 895/1319 (67.9</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title/>
		<author>
			<persName><surname>Ldl-C</surname></persName>
		</author>
		<idno type="DOI">10.7717/peerj.19104/fig-1</idno>
		<idno>945/1233 (76.6</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_reaX72v">mmol/L 2</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">1</biblScope>
		</imprint>
	</monogr>
	<note>1.06) 2.7 (1.09) LDL-C &gt;1.8 mmol/L 465/608 (76.5) 480/625 (76.8)</note>
	<note type="raw_reference">LDL-C, mmol/L 2.7 (1.12) 2.7 (1.06) 2.7 (1.09) LDL-C &gt;1.8 mmol/L 465/608 (76.5) 480/625 (76.8) 945/1233 (76.6</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_4gYurHY">Achieving guideline levels</title>
		<author>
			<persName><surname>Hdl-C</surname></persName>
		</author>
		<idno type="DOI">10.31857/s0016-77706153-36-17001</idno>
		<idno>LDL-C &lt;1.8 mmol/L 119/608 (19.6) 120/625 (19.2) 239/1233 (19.4) BP &lt;140/90 mm Hg 580/708 (81.9) 614/713 (86.1) 1194/1421 (84.0) Exercising regularly â  447/703 (63.6) 455/713 (63.8) 902/1416 (63.7) Nonsmoker/former smoker 514/708 (72.6) 531/716 (74.2) 1045/1424 (73.4) BMI &lt;25 kg/m 2 148/703 (21.1) 170/706 (24.1) 318/1410 (22.6) All 5 key guideline levels â¡ 4/603 (0.7) 10/614 (1.6) 14/1217 (1</idno>
		<ptr target="http://ahajournals.org" />
	</analytic>
	<monogr>
		<title level="j" xml:id="_mQ6Cawp">mmol/L 1</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">0</biblScope>
			<biblScope unit="page" from="542" to="707" />
		</imprint>
	</monogr>
	<note>0.46) 1.1 (0.41) HDL-C &lt;1 mmol/L 273/633 (43.1) 277/641 (43.2) 550/1274 (43.2) (Continued by on July 2, 2025 Total physical activity, MET min/wk 3514.4 (5934.67) 3336.6 (5671.64) 3425.5 (5803.2) Smoking status Current 194/708 (27.4) 185/716 (25.8) 379/1424 (26.6) Former .2) Achieving â¥4 key guideline levels 90/603 (14.9) 95/614 (15.5) 185/1217 (15.2) â¥5 servings of vegetables per day 25/708 (3.5) 21/715 (2.9) 46/1423 (3.2) â¥2 servings of fruit per day 234/708 (33.1) 197/715 (27.6) 431/1423 (30.3) Medications Â§ ACEI/ARB 563/701 (80.3</note>
	<note type="raw_reference">HDL-C, mmol/L 1.1 (0.34) 1.1 (0.46) 1.1 (0.41) HDL-C &lt;1 mmol/L 273/633 (43.1) 277/641 (43.2) 550/1274 (43.2) (Continued ) Downloaded from http://ahajournals.org by on July 2, 2025 Total physical activity, MET min/wk 3514.4 (5934.67) 3336.6 (5671.64) 3425.5 (5803.2) Smoking status Current 194/708 (27.4) 185/716 (25.8) 379/1424 (26.6) Former 279/708 (39.4) 303/716 (42.3) 582/1424 (40.9) Diabetes 168/708 (23.7) 172/716 (24.0) 340/1424 (23.9) Hypertension 346/708 (48.9) 335/716 (46.8) 681/1424 (47.8) Achieving guideline levels LDL-C &lt;1.8 mmol/L 119/608 (19.6) 120/625 (19.2) 239/1233 (19.4) BP &lt;140/90 mm Hg 580/708 (81.9) 614/713 (86.1) 1194/1421 (84.0) Exercising regularly â  447/703 (63.6) 455/713 (63.8) 902/1416 (63.7) Nonsmoker/former smoker 514/708 (72.6) 531/716 (74.2) 1045/1424 (73.4) BMI &lt;25 kg/m 2 148/703 (21.1) 170/706 (24.1) 318/1410 (22.6) All 5 key guideline levels â¡ 4/603 (0.7) 10/614 (1.6) 14/1217 (1.2) Achieving â¥4 key guideline levels 90/603 (14.9) 95/614 (15.5) 185/1217 (15.2) â¥5 servings of vegetables per day 25/708 (3.5) 21/715 (2.9) 46/1423 (3.2) â¥2 servings of fruit per day 234/708 (33.1) 197/715 (27.6) 431/1423 (30.3) Medications Â§ ACEI/ARB 563/701 (80.3) 542/707 (76.7) 1105/1408 (78.5) Aspirin 689/700 (98.4) 703/709 (99.2) 1392/1409 (98.8) Î²-blocker 589/674 (87.4) 602/695 (86.6) 1191/1369 (87.0) Statin 680/705 (96.5) 690/710 (97.2) 1370/1415 (96.8) Second antiplatelet 612/699 (87.6) 606/708 (85.6) 1218/1407 (86.6) Taking all 5 classes 425/652 (65.2) 417/673 (62.0) 842/1325 (63.5Values are mean (SD) or n (%). ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MET, metabolic equivalent task; and SBP, systolic blood pressure. *Other indicates participants who did not fit the listed race/ethnicity categories. â Participants who reported exercising â¥30 min/d (moderate exercise) on 5 or more days per week.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<author>
			<persName><forename type="first">Ldl-C</forename><surname>â¡of</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">P</forename><surname>Regularly</surname></persName>
		</author>
		<idno type="DOI">10.7554/elife.24771.006</idno>
	</analytic>
	<monogr>
		<title level="m" xml:id="_zYSy6TF">nonsmoking status, and body mass index &lt;25 kg/m 2 . Â§Medication use for each cardioprotective treatment. The numerator is the number of patients stating they were taking the medication at baseline (denominator minus a combination of true missing and physicians not prescribing the medication). The denominator is number randomized minus contraindications (medically significant drug reaction/allergy)</title>
		<imprint/>
	</monogr>
	<note type="raw_reference">â¡Of LDL-C, BP, exercising regularly, nonsmoking status, and body mass index &lt;25 kg/m 2 . Â§Medication use for each cardioprotective treatment. The numerator is the number of patients stating they were taking the medi- cation at baseline (denominator minus a combination of true missing and physicians not prescribing the medication). The denomina- tor is number randomized minus contraindications (medically significant drug reaction/allergy). REFERENCES</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_txwQjyv">A randomized trial of Text2Quit: a text messaging program for smoking cessation</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Abroms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Boal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Simmens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Mendel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Windsor</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amepre.2014.04.010</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6eme4RC">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="242" to="250" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Abroms LC, Boal AL, Simmens SJ, Mendel JA, Windsor RA. A randomized trial of Text2Quit: a text messaging program for smoking cessation. Am J Prev Med. 2014;47:242-250. doi: 10.1016/j.amepre.2014.04.010</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_b6xXuna">Predictors of smoking cessation in a lifestyle-focused text-message support programme delivered to people with coronary heart disease: an analysis from the Tobacco, Exercise and Diet Messages (TEXT ME) randomised clinical trial</title>
		<author>
			<persName><forename type="first">H</forename><surname>Klimis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Marschner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Huben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thiagalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename></persName>
		</author>
		<idno type="DOI">10.1177/1179173x20901486</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6TWJwjB">Tob Use Insights</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1179173X" to="20901486" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Klimis H, Marschner S, Von Huben A, Thiagalingam A, Chow CK. Predictors of smoking cessation in a lifestyle-focused text-message support programme delivered to people with coronary heart disease: an analysis from the Tobacco, Exercise and Diet Messages (TEXT ME) randomised clinical trial. Tob Use In- sights. 2020;13:1179173X20901486. doi: 10.1177/1179173X20901486</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_x9FSZ26">Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease: a randomized clinical trial</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Redfern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Hillis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thakkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Santo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Hackett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jan</forename><forename type="middle">S</forename><surname>Graves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>De Keizer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Barry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename></persName>
		</author>
		<idno type="DOI">10.1001/jama.2015.10945</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hr7mV2S">JAMA</title>
		<imprint>
			<biblScope unit="volume">314</biblScope>
			<biblScope unit="page" from="1255" to="1263" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chow CK, Redfern J, Hillis GS, Thakkar J, Santo K, Hackett ML, Jan S, Graves N, de Keizer L, Barry T, et al. Effect of lifestyle-focused text mes- saging on risk factor modification in patients with coronary heart dis- ease: a randomized clinical trial. JAMA. 2015;314:1255-1263. doi: 10.1001/jama.2015.10945</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_5fUycr8">The role of text messaging in cardiovascular risk factor optimization</title>
		<author>
			<persName><forename type="first">H</forename><surname>Klimis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Chow</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11886-017-0811-8</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mUjW8Qb">Curr Cardiol Rep</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">4</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Klimis H, Khan ME, Kok C, Chow CK. The role of text messaging in car- diovascular risk factor optimization. Curr Cardiol Rep. 2017;19:4. doi: 10.1007/s11886-017-0811-8</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_pxvnFf6">A systematic review and meta-analysis of interventions for weight management using text messaging</title>
		<author>
			<persName><forename type="first">G</forename><surname>Siopis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Chey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Allman-Farinelli</surname></persName>
		</author>
		<idno type="DOI">10.1111/jhn.12207</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZbfeXw8">J Hum Nutr Diet</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">Suppl 2</biblScope>
			<biblScope unit="page" from="1" to="15" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Siopis G, Chey T, Allman-Farinelli M. A systematic review and meta-analysis of interventions for weight management using text messaging. J Hum Nutr Diet. 2015;28(Suppl 2):1-15. doi: 10.1111/jhn.12207</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_3wEXZAT">Mobile phone text-messaging interventions aimed to prevent cardiovascular diseases (Text2PreventCVD): systematic review and individual patient data meta-analysis</title>
		<author>
			<persName><forename type="first">Shariful</forename><surname>Islam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Farmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Bobrow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Maddison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Whittaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Pfaeffli</forename><surname>Dale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Lechner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lear</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Eapen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Niessen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">W</forename></persName>
		</author>
		<idno type="DOI">10.1136/openhrt-2019-001017</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yeMe3jv">Open Heart</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">1017</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shariful Islam SM, Farmer AJ, Bobrow K, Maddison R, Whittaker R, Pfaeffli Dale LA, Lechner A, Lear S, Eapen Z, Niessen LW, et al. Mobile phone text-messaging interventions aimed to prevent cardiovascular diseases (Text2PreventCVD): systematic review and individual patient data meta-anal- ysis. Open Heart. 2019;6:e001017. doi: 10.1136/openhrt-2019-001017</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_mY4hYwV">A mobile phone intervention increases physical activity in people with cardiovascular disease: results from the HEART randomized controlled trial</title>
		<author>
			<persName><forename type="first">R</forename><surname>Maddison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pfaeffli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Whittaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kerr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Leung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dalleck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Carter</surname></persName>
		</author>
		<idno type="DOI">10.1177/2047487314535076</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uJ8TjA3">Eur J Prev Cardiol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="701" to="709" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Maddison R, Pfaeffli L, Whittaker R, Stewart R, Kerr A, Jiang Y, Kira G, Leung W, Dalleck L, Carter K, et al. A mobile phone intervention increases physical activity in people with cardiovascular disease: results from the HEART randomized controlled trial. Eur J Prev Cardiol. 2015;22:701-709. doi: 10.1177/2047487314535076</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_KUYDGGx">Mobile phonebased interventions for smoking cessation</title>
		<author>
			<persName><forename type="first">R</forename><surname>Whittaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Mcrobbie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bullen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rodgers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Gu</surname></persName>
		</author>
		<idno type="DOI">10.1002/14651858.cd006611.pub4</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UT6Q7EM">Cochrane Database Syst Rev</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">6611</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Whittaker R, McRobbie H, Bullen C, Rodgers A, Gu Y. Mobile phone- based interventions for smoking cessation. Cochrane Database Syst Rev. 2016;4:CD006611. doi: 10.1002/14651858.CD006611.pub4</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_qXpYEtB">Mobile phone text messages to support treatment adherence in adults with high blood pressure (SMS-Text Adherence Support [StAR]): a single-blind, randomized trial</title>
		<author>
			<persName><forename type="first">K</forename><surname>Bobrow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Farmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Springer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shanyinde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Brennan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rayner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Namane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Steyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tarassenko</surname></persName>
		</author>
		<idno type="DOI">10.1161/circulationaha.115.017530</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_qFgZB8t">Circulation</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<biblScope unit="page" from="592" to="600" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bobrow K, Farmer AJ, Springer D, Shanyinde M, Yu LM, Brennan T, Rayner B, Namane M, Steyn K, Tarassenko L, et al. Mobile phone text messages to support treatment adherence in adults with high blood pressure (SMS- Text Adherence Support [StAR]): a single-blind, randomized trial. Circulation. 2016;133:592-600. doi: 10.1161/CIRCULATIONAHA.115.017530</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_ZwQpQ2J">Effect of text messaging on risk factor management in patients with coronary heart disease: the CHAT randomized clinical trial</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Spatz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Huo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Horak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Guan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yan</surname></persName>
		</author>
		<idno type="DOI">10.1161/circoutcomes.119.005616</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bTKSkd3">Circ Cardiovasc Qual Outcomes</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">5616</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Zheng X, Spatz ES, Bai X, Huo X, Ding Q, Horak P, Wu X, Guan W, Chow CK, Yan X, et al. Effect of text messaging on risk factor manage- ment in patients with coronary heart disease: the CHAT randomized clinical trial. Circ Cardiovasc Qual Outcomes. 2019;12:e005616. doi: 10.1161/CIRCOUTCOMES.119.005616</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_gtAErpH">Cost-effectiveness of a text message programme for the prevention of recurrent cardiovascular events</title>
		<author>
			<persName><forename type="first">E</forename><surname>Burn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nghiem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jan</forename><forename type="middle">S</forename><surname>Redfern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rodgers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thiagalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Graves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename></persName>
		</author>
		<idno type="DOI">10.1136/heartjnl-2016-31019511a</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_pK5hHkv">Heart</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="893" to="894" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Burn E, Nghiem S, Jan S, Redfern J, Rodgers A, Thiagalingam A, Graves N, Chow CK. Cost-effectiveness of a text message programme for the pre- vention of recurrent cardiovascular events. Heart. 2017;103:893-894. doi: 10.1136/heartjnl-2016-310195 11a .</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_YS2R5RC">Text messages for primary prevention of cardiovascular disease: the TextMe2 randomized clinical trial</title>
		<author>
			<persName><forename type="first">H</forename><surname>Klimis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thiagalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Mcintyre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Marschner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Huben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.ahj.2021.08.009</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BeyNHJq">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">242</biblScope>
			<biblScope unit="page" from="33" to="44" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Klimis H, Thiagalingam A, McIntyre D, Marschner S, Von Huben A, Chow CK. Text messages for primary prevention of cardiovascular disease: the TextMe2 randomized clinical trial. Am Heart J. 2021;242:33-44. doi: 10.1016/j.ahj.2021.08.009</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_Sqtv55h">Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Thakkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Kurup</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Laba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Santo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thiagalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rodgers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Woodward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Redfern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Chow</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamainternmed.2015.7667</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DKptpPz">JAMA Intern Med</title>
		<imprint>
			<biblScope unit="volume">176</biblScope>
			<biblScope unit="page" from="340" to="349" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Thakkar J, Kurup R, Laba TL, Santo K, Thiagalingam A, Rodgers A, Woodward M, Redfern J, Chow CK. Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis. JAMA Intern Med. 2016;176:340-349. doi: 10.1001/jamainternmed.2015.7667</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_d4nucFW">TEXT Messages to Improve Medication Adherence and Secondary Prevention (TEXTMEDS) after acute coronary syndrome: a randomised clinical trial protocol</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thiagalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Santo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thakkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Stepien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Billot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jan</forename><forename type="middle">S</forename><surname>Joshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hillis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2017-019463</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zAqGJpG">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">19463</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chow CK, Thiagalingam A, Santo K, Kok C, Thakkar J, Stepien S, Billot L, Jan S, Joshi R, Hillis GS, et al. TEXT Messages to Improve Medication Adherence and Secondary Prevention (TEXTMEDS) after acute coronary syndrome: a randomised clinical trial protocol. BMJ Open. 2018;8:e019463. doi: 10.1136/bmjopen-2017-019463</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_T5AwYeU">Development of a set of mobile phone text messages designed for prevention of recurrent cardiovascular events</title>
		<author>
			<persName><forename type="first">J</forename><surname>Redfern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thiagalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jan</forename><forename type="middle">S</forename><surname>Whittaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hackett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Mooney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Keizer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hillis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename></persName>
		</author>
		<idno type="DOI">10.1177/2047487312449416</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3gbv7cd">Eur J Prev Cardiol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="492" to="499" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Redfern J, Thiagalingam A, Jan S, Whittaker R, Hackett ML, Mooney J, De Keizer L, Hillis GS, Chow CK. Development of a set of mobile phone text messages designed for prevention of recurrent cardiovascular events. Eur J Prev Cardiol. 2014;21:492-499. doi: 10.1177/2047487312449416</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_tXghZmF">Design considerations in development of a mobile health intervention program: the TEXT ME and TEXTMEDS experience</title>
		<author>
			<persName><forename type="first">J</forename><surname>Thakkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Barry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thiagalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Redfern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Mcewan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rodgers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Chow</surname></persName>
		</author>
		<idno type="DOI">10.2196/mhealth.5996</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JC4D7fb">JMIR Mhealth Uhealth</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">e127</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Thakkar J, Barry T, Thiagalingam A, Redfern J, McEwan AL, Rodgers A, Chow CK. Design considerations in development of a mobile health inter- vention program: the TEXT ME and TEXTMEDS experience. JMIR Mhealth Uhealth. 2016;4:e127. doi: 10.2196/mhealth.5996</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_C3NYbPv">Cardiovascular risk perception and evidence-practice gaps in Australian general practice (the AusHEART study)</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Heeley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Peiris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Weekes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Anderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Chalmers</surname></persName>
		</author>
		<idno type="DOI">10.5694/j.1326-5377.2010.tb03502.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZAVurVj">Med J Aust</title>
		<imprint>
			<biblScope unit="volume">192</biblScope>
			<biblScope unit="page" from="254" to="259" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Heeley EL, Peiris DP, Patel AA, Cass A, Weekes A, Morgan C, Anderson CS, Chalmers JP. Cardiovascular risk perception and evidence-practice gaps in Australian general practice (the AusHEART study). Med J Aust. 2010;192:254-259. doi: 10.5694/j.1326-5377.2010.tb03502.x</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_b3jsHCe">Adherence to medication</title>
		<author>
			<persName><forename type="first">L</forename><surname>Osterberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Blaschke</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmra050100</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_74365tV">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">353</biblScope>
			<biblScope unit="page" from="487" to="497" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497. doi: 10.1056/NEJMra050100</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_eX27X2C">Non-adherence to anti-hypertensive medication in low-and middle-income countries: a systematic review and meta-analysis of 92443 subjects</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Ã</forename><surname>Nielsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Shrestha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Neupane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kallestrup</surname></persName>
		</author>
		<idno type="DOI">10.1038/jhh.2016.31</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_MKx8awg">J Hum Hypertens</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="14" to="21" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nielsen JÃ, Shrestha AD, Neupane D, Kallestrup P. Non-adherence to anti-hypertensive medication in low-and middle-income countries: a sys- tematic review and meta-analysis of 92443 subjects. J Hum Hypertens. 2017;31:14-21. doi: 10.1038/jhh.2016.31</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_9JDg5xf">Text messaging support for patients with diabetes or coronary artery disease (SupportMe): protocol for a pragmatic randomised controlled trial</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">W</forename><surname>Cheung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Redfern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thiagalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Hng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sms</forename><surname>Islam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Haider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Faruquie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chow</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2018-025923</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_97QDFt4">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">25923</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note>SupportMe investigators</note>
	<note type="raw_reference">Cheung NW, Redfern J, Thiagalingam A, Hng TM, Islam SMS, Haider R, Faruquie S, Chow C; SupportMe investigators. Text messaging support for patients with diabetes or coronary artery disease (SupportMe): protocol for a pragmatic randomised controlled trial. BMJ Open. 2019;9:e025923. doi: 10.1136/bmjopen-2018-025923</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_GfQMhzm">Design and rationale of the Tobacco, Exercise and Diet Messages (TEXT ME) trial of a text message-based intervention for ongoing prevention of cardiovascular disease in people with coronary disease: a randomised controlled trial protocol</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Redfern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thiagalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jan</forename><forename type="middle">S</forename><surname>Whittaker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hackett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Graves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mooney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hillis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2011-000606</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AU6UNpe">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">606</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chow CK, Redfern J, Thiagalingam A, Jan S, Whittaker R, Hackett M, Graves N, Mooney J, Hillis GS. Design and rationale of the Tobacco, Exercise and Diet Messages (TEXT ME) trial of a text message-based intervention for ongoing prevention of cardiovascular disease in people with coronary dis- ease: a randomised controlled trial protocol. BMJ Open. 2012;2:e000606. doi: 10.1136/bmjopen-2011-000606</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_gEX7pFA">Text messages for primary prevention of cardiovascular disease: the TextMe2 randomised controlled trial protocol</title>
		<author>
			<persName><forename type="first">H</forename><surname>Klimis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thiagalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Chow</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2020-036767</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VY4Agzf">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">36767</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Klimis H, Thiagalingam A, Chow CK. Text messages for primary prevention of cardiovascular disease: the TextMe2 randomised controlled trial protocol. BMJ Open. 2020;10:e036767. doi: 10.1136/bmjopen-2020-036767</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_dXwYx6D">ITM support for patients with chronic respiratory and cardiovascular diseases: a protocol for a randomised controlled trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Redfern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hyun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Singleton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hafiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Raeside</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Spencer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Carr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Caterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cullen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ferry</surname></persName>
		</author>
		<idno type="DOI">10.1136/bmjopen-2018-023863</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kRpnN8e">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">23863</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Redfern J, Hyun K, Singleton A, Hafiz N, Raeside R, Spencer L, Carr B, Caterson I, Cullen J, Ferry C, et al. ITM support for patients with chronic respi- ratory and cardiovascular diseases: a protocol for a randomised controlled trial. BMJ Open. 2019;9:e023863. doi: 10.1136/bmjopen-2018-023863</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_rCEpabk">Suboptimal statin adherence and discontinuation in primary and secondary prevention populations</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Ellis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Erickson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Stevenson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Bernstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Stiles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Fendrick</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1525-1497.2004.30516.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EM84F28">J Gen Intern Med</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="638" to="645" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ellis JJ, Erickson SR, Stevenson JG, Bernstein SJ, Stiles RA, Fendrick AM. Suboptimal statin adherence and discontinuation in primary and second- ary prevention populations. J Gen Intern Med. 2004;19:638-645. doi: 10.1111/j.1525-1497.2004.30516.x</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_uSm4Kr7">Effect of medication adherence on blood pressure control and risk factors for antihypertensive medication adherence</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Yue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Bin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Weilin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Aifang</surname></persName>
		</author>
		<idno type="DOI">10.1111/jep.12268</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mtgb827">J Eval Clin Pract</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="166" to="172" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yue Z, Bin W, Weilin Q, Aifang Y. Effect of medication adherence on blood pressure control and risk factors for antihypertensive medication adher- ence. J Eval Clin Pract. 2015;21:166-172. doi: 10.1111/jep.12268</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_JXsdJe6">Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Lacro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Dunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Dolder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Leckband</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">V</forename><surname>Jeste</surname></persName>
		</author>
		<idno type="DOI">10.4088/jcp.v63n1007</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YsMs93J">J Clin Psychiatry</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="892" to="909" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892- 909. doi: 10.4088/jcp.v63n1007</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_qN62GXn">Adherence to antihypertensive treatment and associated factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Ambaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Alemie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W/</forename><surname>Yohannes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Mengesha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">B</forename></persName>
		</author>
		<idno type="DOI">10.1186/1471-2458-12-282</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rv8SFwT">BMC Public Health</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">282</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ambaw AD, Alemie GA, W/Yohannes SM, Mengesha ZB. Adherence to an- tihypertensive treatment and associated factors among patients on follow up at University of Gondar Hospital, Northwest Ethiopia. BMC Public Health. 2012;12:282. doi: 10.1186/1471-2458-12-282</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_a9mpMq6">Medication adherence influencing factors-an (updated) overview of systematic reviews</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mathes</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13643-019-1014-8</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RM2dGqg">Syst Rev</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">112</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gast A, Mathes T. Medication adherence influencing factors-an (updated) overview of systematic reviews. Syst Rev. 2019;8:112. doi: 10.1186/ s13643-019-1014-8</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_d6xEeSG">Reasons for adherence with antihypertensive medication</title>
		<author>
			<persName><forename type="first">S</forename><surname>Svensson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">I</forename><surname>Kjellgren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ahlner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>SÃ¤ljÃ¶</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0167-5273(00)00374-0</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hVnE2kg">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="157" to="163" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Svensson S, Kjellgren KI, Ahlner J, SÃ¤ljÃ¶ R. Reasons for adherence with antihypertensive medication. Int J Cardiol. 2000;76:157-163. doi: 10.1016/s0167-5273(00)00374-0</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_Fwm3EP6">Medication adherence among hypertensive patients of primary health clinics in Malaysia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ramli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Ahmad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Paraidathathu</surname></persName>
		</author>
		<idno type="DOI">10.2147/PPA.S34704</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_H74SFeB">Patient Prefer Adherence</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="613" to="622" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ramli A, Ahmad NS, Paraidathathu T. Medication adherence among hyper- tensive patients of primary health clinics in Malaysia. Patient Prefer Adher- ence. 2012;6:613-622. doi: 10.2147/PPA.S34704</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_2xCrxkP">Patient nonadherence to medication in inflammatory bowel disease</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Sewitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Abrahamowicz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Barkun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bitton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">E</forename><surname>Wild</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Dobkin</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1572-0241.2003.07522.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_M8fsjkY">Am J Gastroenterol</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="1535" to="1544" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Cohen A, Dobkin PL. Patient nonadherence to medication in inflammatory bow- el disease. Am J Gastroenterol. 2003;98:1535-1544. doi: 10.1111/j. 1572-0241.2003.07522.x</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_fsKPdts">Text message analysis using machine learning to assess predictors of engagement with mobile health chronic disease prevention programs: content analysis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Klimis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Nothman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">W</forename><surname>Cheung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Redfern</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Thiagalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Chow</surname></persName>
		</author>
		<idno type="DOI">10.2196/27779</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8QnE9xt">JMIR Mhealth Uhealth</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">27779</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Klimis H, Nothman J, Lu D, Sun C, Cheung NW, Redfern J, Thiagalingam A, Chow CK. Text message analysis using machine learning to assess predictors of engagement with mobile health chronic disease prevention programs: content analysis. JMIR Mhealth Uhealth. 2021;9:e27779. doi: 10.2196/27779</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_264Dhdf">Utilizing mobile technologies to improve physical activity and medication adherence in patients with heart failure and diabetes mellitus: rationale and design of the TARGET-HF-DM trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Mentz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Granger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Heitner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Banerjee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Majumdar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Eapen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Hudson</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ahj.2019.01.007</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5wUNVKe">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">211</biblScope>
			<biblScope unit="page" from="22" to="33" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sharma A, Mentz RJ, Granger BB, Heitner JF, Cooper LB, Banerjee D, Green CL, Majumdar MD, Eapen Z, Hudson L, et al. Utilizing mo- bile technologies to improve physical activity and medication adherence in patients with heart failure and diabetes mellitus: rationale and de- sign of the TARGET-HF-DM trial. Am Heart J. 2019;211:22-33. doi: 10.1016/j.ahj.2019.01.007</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
